Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Corrigendum
Current Issue
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letters to Editor
Literature Review
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Corrigendum
Current Issue
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letters to Editor
Literature Review
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
View/Download PDF

Translate this page into:

Letters to Editor
19 (
4
); 172-173
doi:
10.4103/0971-4065.59343

Prevalence and association of hepatitis C viremia in hemodialysis patients at a tertiary care hospital

Department of Nephrology, AIIMS, New Delhi, India

Address for correspondence: Dr. Sanjay Kumar Agarwal, Professor and Head, Department of Nephrology, AIIMS, New Delhi, India. E-mail: skagarwal58@yahoo.co.in

Licence

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer:
This article was originally published by Medknow Publications and was migrated to Scientific Scholar after the change of Publisher.

Sir,

I have read with interest the article by Jasuja et al., published in the recent issue of your esteemed journal.[1] I have some observation to make.

  1. Indian references are conspicuously absent. Author has quoted references from France, Moldova and Syria and not from our own country. There is not a single reference from India, though there are 13 articles published in indexed journals alone.[214]

  2. The author has stated in the introduction that duration of end-stage renal disease is one of the risk factors for prevalence of HCV in dialysis. I think this is not supported with the literature.

  3. I fail to understand the basis of exclusion of patients with HCV who were receiving treatment. After all, they also create pool of patients contributing to overall prevalence.

  4. Some centers are reusing dialyzer of HCV patients but in a different area. It is more important to specify that the reuse variable included in this study has taken this issue or not, and, if yes, then what was percentage of reuse being done in a separate area.

  5. I would like to know the period of study; from the year of beginning to year of completion. 119 patients are from how many patients being dialysed during the period of study.

  6. The hepatitis vaccination in hemodialysis patients is a 4-dose schedule. Hence, authors write that twice or more vaccination in 10 patients (8.4%) does not make any sense. Because it may still be inadequate vaccination. The author should mention full vaccination vs. inadequate vaccination. I am also not sure how HBV vaccination, which the author has analyzed, will affect HCV prevalence.

  7. As the author performed the HCV test at the time of accepting patients on dialysis, they should mention the number of patients who already had HCV when they were accepted in their unit, and how many were actually new infection.

  8. I am unable to understand how the author reached to the time for onset of CRF. In practical sense, we usually do not have serial values to determine the exact onset of CRF (CKD) in a majority of patients.

  9. In the ROC curve, it is better to say at what duration of dialysis, patients will be HCV positive and with what probability. For example, after 20 months of dialysis, 50% chance is that a patient will be HCV positive. The findings presented by the authors seem odd. According to their criteria, additional dialysis from the 15th to 16th month, that is, for 1 month will change the prevalence of HCV from 7.4% to 45.2%. This, I think, is not possible. Authors themselves later conclude that increase in dialysis for one month increased the odds of HCV positivity by 1.06 times. This means that representation by the ROC criteria is not appropriate and can mislead the reader.

  10. Authors have not mentioned other causes of increased liver enzyme, such as antitubercular drugs, while correlating the enzyme values with HCV positivity. About 12%-15% patients in any dialysis program in India have tuberculosis and they are on drugs. This issue has not been mentioned at all in the results or discussion.

  11. In discussion, the authors are mentioning higher ALT as a risk factor for HCV infection, which is never a case. A higher ALT is in fact is the result of HCV infection.

  12. The author describes that they do not isolate HCV patients and their HCV prevalence is 27.8%, which by any standard is not low. They should mention the new cases of HCV in their unit and only then they can explain that whether their not isolating HCV-positive patient is justified.

References

  1. , , , , , , . Prevalence and association of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. Indian J Nephrol. 2009;19:62-8.
    [Google Scholar]
  2. , , , , , , . Diagnostic utility of hepatitis C virus core antigen in hemodialysis patients. Clin Biochem. 2008;41:447-52.
    [Google Scholar]
  3. , , . Evaluation of commercially available third-generation anti-hepatitis C virus enzyme-linked immunosorbent assay in patients on haemodialysis. Indian J Med Microbiol. 2007;25:140-2.
    [Google Scholar]
  4. , , , . Seroprevalence of hepatitis C virus (HCV) in health care workers of a tertiary care centre in New Delhi. Indian J Med Res. 2006;123:179-80.
    [Google Scholar]
  5. , , . Utility of HCV core antigen ELISA in the screening for hepatitis C virus infection in patients on hemodialysis. Indian J Med Microbiol. 2006;24:55-7.
    [Google Scholar]
  6. , , , , . Prevalence of transfusion-transmitted virus infection in patients on maintenance hemodialysis from New Delhi, India. Hemodial Int. 2005;9:362-6.
    [Google Scholar]
  7. , , . Prevalence of HCV infection in patients on haemodialysis: Survey by antibody and core antigen detection. Indian J Med Microbiol. 2005;23:106-10.
    [Google Scholar]
  8. , , , , . Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol. 2005;23:41-3.
    [Google Scholar]
  9. , , , , , , . Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure. Intervirology. 2004;47:374-6.
    [Google Scholar]
  10. , . Hepatitis and HIV infection during haemodialysis. J Indian Med Assoc. 2001;99:194-9, 203, 213.
    [Google Scholar]
  11. , , . Hepatitis C virus infection during haemodialysis in India. J Assoc Physicians India. 1999;47:1139-43.
    [Google Scholar]
  12. , , , , , . Prevalence of hepatitis C virus (HCV) infection in Mumbai. Indian J Med Sci. 1997;51:378-85.
    [Google Scholar]
  13. , , , , , , . Prevalence of anti-HCV antibodies in central India. Indian J Med Res. 1996;104:177-81.
    [Google Scholar]
  14. , , , , . Prevalence of anti-HCV antibodies in western India. Indian J Med Res. 1995;101:91-3.
    [Google Scholar]

Fulltext Views
154

PDF downloads
126
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections